Vancomycin-Intermediate Staphylococcus aureus in a Home Health-Care Patient
Jeffrey C. Hageman* , David A. Pegues†, Carrie Jepson‡, Rose Lee Bell‡, Mary Guinan§, Kevin W. Ward†, Martin D. Cohen†, Janet A. Hindler†, Fred C. Tenover*, Sigrid K. McAllister*, Molly E. Kellum*, and Scott K. Fridkin*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;; †University of California Los Angeles Medical Center, Los Angeles, California, USA;; ‡Clark County Health District, Las Vegas, Nevada, USA;; §Nevada State Health Division, Carson City, Nevada, USA
Figure 2. Pulsed-field gel electrophoresis profiles of SmaI digested DNA. NCTC, National Collection of Type Cultures 8325 control. Lane 1, vancomycin-intermediate Staphylococcus aureus (VISA) isolate from Japan, otherwise designated Mu50; lane 2, VISA isolate from Michigan (7); lane 3, VISA isolate from New Jersey (7); Lane 4, VISA isolate from New York (1); lane 5, VISA isolate from Illinois (3); lane 7, patient's oxacillin-resistant VISA; lane 8, patient's oxacillin-susceptible VISA; lane 9 patient's oxacillin-resistant S. aureus (ORSA, vancomycin MIC = 2 µg/mL) from anterior nares; lanes 10 and 11, isolates of ORSA (vancomycin MIC=2 µg/mL) from the health-care worker's anterior nares.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.